Q1 2022 Results

Company overview CRM Financial performance Immunology Financial review Neuroscience EntrestoⓇ - 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors References Abbreviations Hematology Biosimilars Angiotensin receptor/neprilysin inhibitor Global Health Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT02678312 PANORAMA HF (CLCZ696B2319) Heart failure in pediatric patients Phase 3 377 Part 1: Pharmacodynamics and pharmacokinetics of sacubitril/valsartan LCZ696 analytes Part 2: Efficacy and safety compared with enalapril Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; 0.4 mg/kg or 1.6 mg/kg or both (single doses). Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction NCT02884206 PERSPECTIVE (CLCZ696B2320) Heart failure Phase 3 592 Change from baseline in the CogState Global Cognitive Composite Score (GCCS) Sacubitril/valsartan 50, 100, and 200 mg bid with placebo of valsartan Valsartan 40, 80, and 160 mg bid tablets with placebo for sacubitril/valsartan Patients with chronic heart failure with preserved ejection fraction Target Patients Read-out Milestone(s) 2022; (Analysis of 110 pts from Part 2 formed the basis for pediatric submission in Apr-2019 and approval by the US FDA in Oct-2019 for the treatment of symptomatic HF with systemic left ventricular systolic dysfunction in children aged 1 year and older) 2023 Publication TBD TBD 46 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation